Icosavax, Inc. (NASDAQ:ICVX) Insider Cassia Cearley Sells 10,000 Shares

Icosavax, Inc. (NASDAQ:ICVX – Get Rating) insider Cassia Cearley sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, May 23rd. The stock was sold at an average price of $10.00, for a total value of $100,000.00. Following the completion of the transaction, the insider now owns 141,847 shares of the company’s stock, valued at approximately $1,418,470. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Cassia Cearley also recently made the following trade(s):

• On Monday, March 6th, Cassia Cearley sold 5,000 shares of Icosavax stock. The stock was sold at an average price of $7.75, for a total value of $38,750.00.

Icosavax Stock Performance

Shares of NASDAQ ICVX opened at $9.31 on Friday. Icosavax, Inc. has a 52 week low of $2.28 and a 52 week high of $16.45. The business has a 50-day simple moving average of $6.67 and a two-hundred day simple moving average of $7.17.

Icosavax (NASDAQ:ICVX – Get Rating) last issued its earnings results on Thursday, March 30th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.01). On average, equities research analysts expect that Icosavax, Inc. will post -2.48 EPS for the current fiscal year.

Institutional Trading of Icosavax

Large investors have recently modified their holdings of the business. Tower Research Capital LLC TRC raised its stake in Icosavax by 716.5% in the third quarter. Tower Research Capital LLC TRC now owns 13,937 shares of the company’s stock valued at $44,000 after purchasing an additional 12,230 shares in the last quarter. Barclays PLC lifted its holdings in shares of Icosavax by 505.6% during the 4th quarter. Barclays PLC now owns 6,020 shares of the company’s stock worth $47,000 after acquiring an additional 5,026 shares during the last quarter. Renaissance Technologies LLC purchased a new position in Icosavax in the third quarter worth $48,000. BNP Paribas Arbitrage SNC bought a new position in Icosavax in the third quarter valued at $60,000. Finally, Jump Financial LLC purchased a new stake in Icosavax during the first quarter valued at about $66,000. Institutional investors own 80.54% of the company’s stock.

Icosavax Company Profile

(Get Rating)

Icosavax, Inc, a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial.